Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VOLITIONRX LTDVNRX · Entity 8241 | Director | February 26, 2026 | February 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VOLITIONRX LTD
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,252,967 |
Reported balance
After 2026-02-26 transaction · row 1
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 178,000 · Balance 1,252,967 F1: On February 26, 2026, the reporting person was awarded 178,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on February 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy The Innes Family Bare Trust 2023 | 1,400,000 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,400,000 F2: These shares of Common Stock are beneficially owned by The Innes Family Bare Trust 2023, which is a separate legal entity, of which the reporting person is the Trustee, for the benefit of his children. |
| Common StockSEC Table I · non-derivative | IndirectBy The Dill Faulkes Educational Trust Limited | 356,000 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 356,000 F3: These shares of Common Stock are beneficially owned by The Dill Faulkes Educational Trust Limited ("DFET"), a UK registered charity. The reporting person serves as a director and trustee of DFET and shares voting and dispositive control over these shares but disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy son | 154,503 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 154,503 |
| Common StockSEC Table I · non-derivative | IndirectBy son | 154,503 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 154,503 |
| Common StockSEC Table I · non-derivative | IndirectBy daughter | 154,504 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 154,504 |
| Common StockSEC Table I · non-derivative | IndirectBy daughter | 154,504 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 154,504 |
Filing footnotes · ownership attribution and instrument terms
F1: On February 26, 2026, the reporting person was awarded 178,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on February 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date.
F2: These shares of Common Stock are beneficially owned by The Innes Family Bare Trust 2023, which is a separate legal entity, of which the reporting person is the Trustee, for the benefit of his children.
F3: These shares of Common Stock are beneficially owned by The Dill Faulkes Educational Trust Limited ("DFET"), a UK registered charity. The reporting person serves as a director and trustee of DFET and shares voting and dispositive control over these shares but disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed Feb 27, 2026 21:30 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 178,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-26-001095 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,252,967 F1 · shares: On February 26, 2026, the reporting person was awarded 178,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on February 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date. Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 21:08 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-26-000372 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,074,967 F1 · shares: On March 17, 2025, the reporting person was awarded 40,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 12,000 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 4,000 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 28,000 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively. Read SEC document |
| October 14, 2025 Filed Oct 15, 2025 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseWarrant (Right to Buy) · Derivative | 96,153 | $0.01 Strike: $0.60 | $961.53 |
DisclosureSEC source: 0001477932-25-007587 · form4.xml · derivative · entry 8 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,153 Underlying: Common Stock · 96,153 shares Expires 2030-10-14 F1 · shares: The shares of common stock and accompanying common stock warrants were purchased by the reporting person from the underwriter in connection with an underwritten public offering by the Issuer. The offering closed on October 14, 2025. The reported sale price reflects the price of $0.52 per share of common stock and accompanying warrant to purchase one additional share of common stock, of which $0.01 of the sale price was allocated to the warrant. Read SEC document |
| October 14, 2025 Filed Oct 15, 2025 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 96,153 | $0.51 | $49,038.03 |
DisclosureSEC source: 0001477932-25-007587 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,062,967 F1 · shares: The shares of common stock and accompanying common stock warrants were purchased by the reporting person from the underwriter in connection with an underwritten public offering by the Issuer. The offering closed on October 14, 2025. The reported sale price reflects the price of $0.52 per share of common stock and accompanying warrant to purchase one additional share of common stock, of which $0.01 of the sale price was allocated to the warrant. Read SEC document |
| August 05, 2025 Filed Aug 6, 2025 13:00 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 78,125 | $0.64 | $50,000.00 |
DisclosureSEC source: 0001477932-25-005495 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 966,814 F1 · shares: Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 11:55 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 20,000 | $0.54 | $10,772.00 |
DisclosureSEC source: 0001477932-25-004394 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 888,689 Read SEC document |
| March 26, 2025 Filed Mar 27, 2025 12:13 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 181,818 | $0.55 | $99,999.90 |
DisclosureSEC source: 0001477932-25-002072 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 868,689 F1 · shares: Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 19,786 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-001456 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 686,871 F1 · shares: On March 1, 2025, the reporting person was awarded 19,786 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 6,596 units, 6,595 units, and 6,595 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $3.25 | Not disclosed |
DisclosureSEC source: 0001477932-25-000613 · form4.xml · derivative · entry 2 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-02-11 F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | Disposition to issuerStock Option (Right to Buy) · Derivative | 25,000 | Not disclosed Strike: $3.25 | Not disclosed |
DisclosureSEC source: 0001477932-25-000613 · form4.xml · derivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-02-11 F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant). Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-25-000326 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 667,085 F1 · shares: The reporting person received 50,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, vesting in three installments of 16,667 units, 16,667 units, and 16,666 units on each of January 15, 2026, January 15, 2027 and January 15, 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 174,764 | $0.57 | $99,999.96 |
DisclosureSEC source: 0001477932-24-007972 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 617,085 F1 · shares: Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 21:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 17,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-007808 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 442,321 F1 · shares: On December 1, 2024, the reporting person was awarded 17,296 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 5,766 units, 5,765 units, and 5,765 units on each of December 1, 2024, January 1, 2025 and February 1, 2025, respectively, are also subject to further time-based vesting in a single installment on July 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 20:04 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 18,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-005505 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,025 F1 · shares: On September 1, 2024, the reporting person was awarded 18,342 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 6,114 units on each of September 1, 2024, October 1, 2024 and November 1, 2024, respectively, are also subject to further time-based vesting in a single installment on June 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 12:26 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 150,000 | $0.67 | $100,500.00 |
DisclosureSEC source: 0001477932-24-005169 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 406,683 Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-005030 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,683 F1 · shares: On Sept 28, 2023, the reporting person was awarded 20,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to Dec 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,000 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 1,666 units, 1,667 units, and 1,667 units on each of Sept 28, 2024, 2025 and 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in Jan 2024, the rights with respect to 8,500 RSUs subject to the award previously vested and remain subject to time-based vesting. The rights with respect to the remaining 6,500 RSUs did not vest and were cancelled on August 15, 2024. Read SEC document |
| July 04, 2024 Filed Jul 5, 2024 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GiftCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-004084 · form4.xml · nonDerivative · entry 2 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Innes Family Bare Trust 2023 Disclosed balance after: 1,400,000 F1 · shares: On July 4, 2024, the reporting person transferred the securities to The Innes Family Bare Trust 2023, which is a separate legal entity, of which the reporting person is the Trustee, for the benefit of his children F1 · ownership.nature: On July 4, 2024, the reporting person transferred the securities to The Innes Family Bare Trust 2023, which is a separate legal entity, of which the reporting person is the Trustee, for the benefit of his children Read SEC document |
| July 04, 2024 Filed Jul 5, 2024 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GiftCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-004084 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,683 F1 · shares: On July 4, 2024, the reporting person transferred the securities to The Innes Family Bare Trust 2023, which is a separate legal entity, of which the reporting person is the Trustee, for the benefit of his children Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 16,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-003485 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 651,683 F1 · shares: On June 1, 2024, the reporting person was awarded 16,022 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 5,341 units, 5,341 units, and 5,340 units on each of June 1, 2024, July 1, 2024 and August 1, 2024, respectively, are also subject to further time-based vesting in a single installment on May 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-24-000414 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 635,661 F1 · shares: On September 28, 2023, the reporting person was awarded 20,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 8,500 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 2,834 units, 2,833 units, and 2,833 units on each of September 28, 2024, September 28, 2025 and September 28, 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. Read SEC document |
| November 27, 2023 Filed Nov 28, 2023 14:39 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 20,000 | $0.77 | $15,400.00 |
DisclosureSEC source: 0001477932-23-008822 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,161 Read SEC document |
| November 24, 2023 Filed Nov 27, 2023 15:28 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 10,000 | $0.76 | $7,600.00 |
DisclosureSEC source: 0001477932-23-008798 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 607,161 Read SEC document |
| November 22, 2023 Filed Nov 24, 2023 16:06 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 20,000 | $0.71 | $14,200.00 |
DisclosureSEC source: 0001477932-23-008792 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 597,161 Read SEC document |
| July 05, 2023 Filed Jul 7, 2023 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 6,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-005108 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 577,161 F1 · shares: On October 4, 2022, the reporting person was awarded 15,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 6,750 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 2,250 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in October 2022 and January 2023 respectively, the rights with respect to 2,625 RSUs and 5,625 RSUs subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GiftCommon stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-004896 · form4.xml · nonDerivative · entry 2 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By The Innes Family Bare Trust 2023 Disclosed balance after: 1,000,000 F1 · shares: On June 27, 2023, the reporting person transferred the securities to The Innes Family Bare Trust 2023, which is a separate legal entity, of which the reporting person is the Trustee, for the benefit of his children. F1 · ownership.nature: On June 27, 2023, the reporting person transferred the securities to The Innes Family Bare Trust 2023, which is a separate legal entity, of which the reporting person is the Trustee, for the benefit of his children. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GiftCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-004896 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 570,411 F1 · shares: On June 27, 2023, the reporting person transferred the securities to The Innes Family Bare Trust 2023, which is a separate legal entity, of which the reporting person is the Trustee, for the benefit of his children. Read SEC document |
| February 22, 2023 Filed Feb 23, 2023 20:54 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 58,500 | $1.75 | $102,375.00 |
DisclosureSEC source: 0001477932-23-001225 · form4.xml · nonDerivative · entry 4 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 154,504 F1 · shares: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F1 · ownership.nature: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 22, 2023 Filed Feb 23, 2023 20:54 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 58,500 | $1.75 | $102,375.00 |
DisclosureSEC source: 0001477932-23-001225 · form4.xml · nonDerivative · entry 3 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 154,504 F1 · shares: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F1 · ownership.nature: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 22, 2023 Filed Feb 23, 2023 20:54 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 58,500 | $1.75 | $102,375.00 |
DisclosureSEC source: 0001477932-23-001225 · form4.xml · nonDerivative · entry 2 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 154,503 F1 · shares: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F1 · ownership.nature: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| February 22, 2023 Filed Feb 23, 2023 20:54 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 58,500 | $1.75 | $102,375.00 |
DisclosureSEC source: 0001477932-23-001225 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 154,503 F1 · shares: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F1 · ownership.nature: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 21:02 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 5,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-23-000266 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,570,411 F1 · shares: On October 4, 2022, the reporting person was awarded 15,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,625 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 1,875 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in October 2022, the rights with respect to 2,625 restricted stock units subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GiftCommon Stock | 12,432 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-008314 · form4.xml · nonDerivative · entry 9 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 96,004 F2 · shares: The foregoing shares were held by a bare trust, which was not a separate legal entity, of which the reporting person was the Trustee, for the benefit of his children. The bare trust was wound up and the securities transferred to the children of the reporting person. F2 · ownership.nature: The foregoing shares were held by a bare trust, which was not a separate legal entity, of which the reporting person was the Trustee, for the benefit of his children. The bare trust was wound up and the securities transferred to the children of the reporting person. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GiftCommon Stock | 12,432 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-008314 · form4.xml · nonDerivative · entry 8 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 96,004 F2 · shares: The foregoing shares were held by a bare trust, which was not a separate legal entity, of which the reporting person was the Trustee, for the benefit of his children. The bare trust was wound up and the securities transferred to the children of the reporting person. F2 · ownership.nature: The foregoing shares were held by a bare trust, which was not a separate legal entity, of which the reporting person was the Trustee, for the benefit of his children. The bare trust was wound up and the securities transferred to the children of the reporting person. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GiftCommon Stock | 12,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-008314 · form4.xml · nonDerivative · entry 7 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 96,003 F2 · shares: The foregoing shares were held by a bare trust, which was not a separate legal entity, of which the reporting person was the Trustee, for the benefit of his children. The bare trust was wound up and the securities transferred to the children of the reporting person. F2 · ownership.nature: The foregoing shares were held by a bare trust, which was not a separate legal entity, of which the reporting person was the Trustee, for the benefit of his children. The bare trust was wound up and the securities transferred to the children of the reporting person. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GiftCommon Stock | 12,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-008314 · form4.xml · nonDerivative · entry 6 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 96,003 F2 · shares: The foregoing shares were held by a bare trust, which was not a separate legal entity, of which the reporting person was the Trustee, for the benefit of his children. The bare trust was wound up and the securities transferred to the children of the reporting person. F2 · ownership.nature: The foregoing shares were held by a bare trust, which was not a separate legal entity, of which the reporting person was the Trustee, for the benefit of his children. The bare trust was wound up and the securities transferred to the children of the reporting person. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GiftCommon Stock | 49,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-008314 · form4.xml · nonDerivative · entry 5 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Bare Trust Disclosed balance after: 0 F2 · shares: The foregoing shares were held by a bare trust, which was not a separate legal entity, of which the reporting person was the Trustee, for the benefit of his children. The bare trust was wound up and the securities transferred to the children of the reporting person. F2 · ownership.nature: The foregoing shares were held by a bare trust, which was not a separate legal entity, of which the reporting person was the Trustee, for the benefit of his children. The bare trust was wound up and the securities transferred to the children of the reporting person. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | OtherCommon Stock | 8,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-008314 · form4.xml · nonDerivative · entry 4 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 83,572 F1 · shares: Bequeathed to the children of the reporting person by parties other than the reporting person pursuant to the terms of a will. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F1 · ownership.nature: Bequeathed to the children of the reporting person by parties other than the reporting person pursuant to the terms of a will. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | OtherCommon Stock | 8,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-008314 · form4.xml · nonDerivative · entry 3 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 83,572 F1 · shares: Bequeathed to the children of the reporting person by parties other than the reporting person pursuant to the terms of a will. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F1 · ownership.nature: Bequeathed to the children of the reporting person by parties other than the reporting person pursuant to the terms of a will. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | OtherCommon Stock | 8,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-008314 · form4.xml · nonDerivative · entry 2 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 83,572 F1 · shares: Bequeathed to the children of the reporting person by parties other than the reporting person pursuant to the terms of a will. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F1 · ownership.nature: Bequeathed to the children of the reporting person by parties other than the reporting person pursuant to the terms of a will. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 21:05 UTC | VOLITIONRX LTD VNRX · Entity 8241 | OtherCommon Stock | 8,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-008314 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 83,572 F1 · shares: Bequeathed to the children of the reporting person by parties other than the reporting person pursuant to the terms of a will. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F1 · ownership.nature: Bequeathed to the children of the reporting person by parties other than the reporting person pursuant to the terms of a will. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 13, 2022 Filed Oct 14, 2022 20:03 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-007694 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,564,786 F1 · shares: On October 4, 2022, the reporting person was awarded 15,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 2,625 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 875 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 75,000 | $2.00 | $150,000.00 |
DisclosureSEC source: 0001477932-22-005632 · form4.xml · nonDerivative · entry 5 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 75,000 F2 · shares: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F2 · ownership.nature: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 75,000 | $2.00 | $150,000.00 |
DisclosureSEC source: 0001477932-22-005632 · form4.xml · nonDerivative · entry 4 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By daughter Disclosed balance after: 75,000 F2 · shares: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F2 · ownership.nature: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 75,000 | $2.00 | $150,000.00 |
DisclosureSEC source: 0001477932-22-005632 · form4.xml · nonDerivative · entry 3 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 75,000 F2 · shares: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F2 · ownership.nature: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 75,000 | $2.00 | $150,000.00 |
DisclosureSEC source: 0001477932-22-005632 · form4.xml · nonDerivative · entry 2 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By son Disclosed balance after: 75,000 F2 · shares: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. F2 · ownership.nature: Acquired by the reporting person's child at the public offering price in the public offering of common stock by the Company. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 12,500 | $2.00 | $25,000.00 |
DisclosureSEC source: 0001477932-22-005632 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,562,161 F1 · shares: Acquired at the public offering price in the public offering of common stock by the Company. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:04 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 5,613 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001477932-22-004663 · form4.xml · derivative · entry 4 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,635 Underlying: Common Stock · 5,613 shares Expires 2031-08-03 F4 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,613 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,807 shares and 2,806 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 3,022 shares subject to the award previously vested and remain subject to time-based vesting. F4 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,613 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 2,807 shares and 2,806 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 3,022 shares subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:04 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantCommon Stock | 3,046 | $0.00 | $0.00 |
DisclosureSEC source: 0001477932-22-004663 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,549,661 F1 · shares: On August 3, 2021, the reporting person was awarded 4,686 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,046 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 1,523 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 1,640 restricted stock units subject to the award previously vested and remain subject to time-based vesting. Read SEC document |
| May 16, 2022 Filed May 17, 2022 15:37 UTC | VOLITIONRX LTD VNRX · Entity 8241 | PurchaseCommon Stock | 10,000 | $2.37 | $23,700.00 |
DisclosureSEC source: 0001477932-22-003572 · form4.xml · nonDerivative · entry 1 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,546,615 Read SEC document |
| April 07, 2022 Filed Apr 8, 2022 20:01 UTC | VOLITIONRX LTD VNRX · Entity 8241 | GrantStock Option (Right to Buy) · Derivative | 3,022 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001477932-22-002176 · form4.xml · derivative · entry 4 Innes Guy Archibald · CIK 0001579377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,022 Underlying: Common Stock · 3,022 shares Expires 2031-08-03 F4 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,022 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,511 shares on each of August 3, 2022 and August 3, 2023, respectively. F4 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 8,635 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 3,022 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 1,511 shares on each of August 3, 2022 and August 3, 2023, respectively. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.